Egyptian International Pharmaceutical Investments (CAI:PHAR) Other Current Liabilities: E£802 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAI:PHAR Egyptian International Pharmaceutical Investments CAI:PHAR
64 GF Score
Price E£117.80
GF Value E£60.97
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Egyptian International Pharmaceutical Investments Other Current Liabilities?

Egyptian International Pharmaceutical Investments CAI:PHAR +0.03% 64 Other Current Liabilities is E£802 Mil as of Sep. 2025. GuruFocus rates CAI:PHAR with a GF Score™ of 64/100 and a GF Value™ of E£60.97 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Egyptian International Pharmaceutical Investments's other current liabilities for the quarter that ended in Sep. 2025 was E£802 Mil.

Egyptian International Pharmaceutical Investments's quarterly other current liabilities declined from Mar. 2025 (E£1,259 Mil) to Jun. 2025 (E£795 Mil) but then increased from Jun. 2025 (E£795 Mil) to Sep. 2025 (E£802 Mil).

Egyptian International Pharmaceutical Investments's annual other current liabilities increased from Dec. 2022 (E£280 Mil) to Dec. 2023 (E£391 Mil) and increased from Dec. 2023 (E£391 Mil) to Dec. 2024 (E£580 Mil).

Egyptian International Pharmaceutical Investments Other Current Liabilities Related Terms

Egyptian International Pharmaceutical Investments Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Egyptian International Pharmaceutical Investments's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egyptian International Pharmaceutical Investments Other Current Liabilities Chart

Egyptian International Pharmaceutical Investments Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 206.92 189.54 279.55 390.82 580.45

Egyptian International Pharmaceutical Investments Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 512.43 580.45 1,258.69 794.69 801.80
CAI:PHAR
64GF Score
Egyptian International Pharmaceutical Investments CAI:PHAR
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Egyptian International Pharmaceutical Investments Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of E£802 Mil mean?
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a Other Current Liabilities of E£802 Mil as of Sep. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Egyptian International Pharmaceutical Investments.
Is Egyptian International Pharmaceutical Investments' Other Current Liabilities too high?
Egyptian International Pharmaceutical Investments' current Other Current Liabilities is E£802 Mil. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' Other Current Liabilities compare to ZTS and UTHR?
Egyptian International Pharmaceutical Investments' Other Current Liabilities of E£802 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Egyptian International Pharmaceutical Investments. Egyptian International Pharmaceutical Investments's current Other Current Liabilities is E£802 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£60.97, compared to a current price of E£117.80 — trading 93.2% above its estimated fair value. The current Other Current Liabilities is E£802 Mil. Egyptian International Pharmaceutical Investments' overall GF Score™ is 64/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current Other Current Liabilities is E£802 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued. The current stock price of E£117.80 is trading 93.2% above its estimated GF Value™ of E£60.97. GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.

Key valuation signals for CAI:PHAR:

  • Other Current Liabilities: E£802 Mil
  • GF Value™: E£60.97 vs. price of E£117.80 (93.2% above fair value)
  • GF Score™: 64/100 with 10 warning signs

No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Egyptian International Pharmaceutical Investments Business Description

Address 1st Industrial Zone B1, EIPICO, Tenth of Ramadan City, EGY
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
64GF Score

Get the complete analysis for CAI:PHAR

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£117.80
Price
E£60.97
GF Value